Bioventus Inc. (BVS)

Market Cap	600.92M -9.4%
Revenue (ttm)	568.09M -0.9%
Net Income	22.73M
EPS	0.33
Shares Out	67.37M
PE Ratio	27.03
Forward PE	11.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,941
Open	8.92
Previous Close	8.99
Day's Range	8.82 - 9.02
52-Week Range	5.81 - 10.13
Beta	0.72
Analysts	Strong Buy
Price Target	14.25 (+59.75%)
Earnings Date	Mar 5, 2026

About BVS

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 2021
• Employees: 930
• Stock Exchange: NASDAQ
• Ticker Symbol: BVS
• Website: https://www.bioventus.com

Analyst Summary

According to 4 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 59.75% from the latest price.

Price Target

$14.25

(59.75% upside)

Analyst Consensus: Strong Buy